Barry J. Maurer

1.6k total citations
40 papers, 1.3k citations indexed

About

Barry J. Maurer is a scholar working on Molecular Biology, Neurology and Ophthalmology. According to data from OpenAlex, Barry J. Maurer has authored 40 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 10 papers in Neurology and 6 papers in Ophthalmology. Recurrent topics in Barry J. Maurer's work include Retinoids in leukemia and cellular processes (21 papers), Neuroblastoma Research and Treatments (10 papers) and Sphingolipid Metabolism and Signaling (9 papers). Barry J. Maurer is often cited by papers focused on Retinoids in leukemia and cellular processes (21 papers), Neuroblastoma Research and Treatments (10 papers) and Sphingolipid Metabolism and Signaling (9 papers). Barry J. Maurer collaborates with scholars based in United States, South Korea and Germany. Barry J. Maurer's co-authors include C. Patrick Reynolds, Richard Kolesnick, Katherine K. Matthay, Judith G. Villablanca, Min H. Kang, Sandeep Batra, Giuseppe Attardi, Eric Lai, Barbara A. Hamkalo and Leroy Hood and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

Barry J. Maurer

39 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barry J. Maurer United States 17 1.0k 293 164 151 128 40 1.3k
Antonio F. Santidrián Spain 21 1.2k 1.1× 149 0.5× 429 2.6× 281 1.9× 77 0.6× 30 1.8k
Ghita Ghislat United Kingdom 16 765 0.7× 73 0.2× 105 0.6× 151 1.0× 269 2.1× 22 1.5k
Petra Obexer Austria 24 1.2k 1.2× 159 0.5× 396 2.4× 325 2.2× 116 0.9× 43 1.8k
Belamy B. Cheung Australia 25 1.3k 1.3× 479 1.6× 289 1.8× 582 3.9× 72 0.6× 61 1.8k
Martin Augustin Germany 21 946 0.9× 88 0.3× 171 1.0× 44 0.3× 141 1.1× 48 1.4k
Raquel García-Medina United States 8 957 0.9× 49 0.2× 164 1.0× 401 2.7× 233 1.8× 10 1.6k
Maria Stella Ritorto United Kingdom 13 1.1k 1.0× 244 0.8× 246 1.5× 126 0.8× 146 1.1× 18 1.5k
Daichao Xu China 19 1.2k 1.2× 107 0.4× 226 1.4× 257 1.7× 191 1.5× 33 1.9k
Thomas P. Garner United Kingdom 19 958 0.9× 70 0.2× 161 1.0× 88 0.6× 170 1.3× 29 1.3k

Countries citing papers authored by Barry J. Maurer

Since Specialization
Citations

This map shows the geographic impact of Barry J. Maurer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry J. Maurer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry J. Maurer more than expected).

Fields of papers citing papers by Barry J. Maurer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry J. Maurer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry J. Maurer. The network helps show where Barry J. Maurer may publish in the future.

Co-authorship network of co-authors of Barry J. Maurer

This figure shows the co-authorship network connecting the top 25 collaborators of Barry J. Maurer. A scholar is included among the top collaborators of Barry J. Maurer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry J. Maurer. Barry J. Maurer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jonnalagadda, Sravan K., Ling Duan, Elizabeth A. Kosmacek, et al.. (2024). Coumarin‐Based Aldo‐Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors. ChemMedChem. 19(21). e202400081–e202400081. 1 indexed citations
2.
Maurer, Barry J., Min H. Kang, C. Patrick Reynolds, et al.. (2023). Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies. Cancer Chemotherapy and Pharmacology. 92(2). 97–105. 3 indexed citations
3.
Wei, Sung‐Jen, In‐Hyoung Yang, Thinh H. Nguyen, et al.. (2023). DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 1866(2). 194939–194939. 4 indexed citations
4.
Thomas, Jacob, Anthony B. El-Khoueiry, Barry J. Maurer, et al.. (2021). A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemotherapy and Pharmacology. 87(4). 525–532. 14 indexed citations
5.
6.
Song, Michael M., Monish Ram Makena, Ashly Hindle, et al.. (2018). Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. Anti-Cancer Drugs. 30(2). 117–127. 11 indexed citations
7.
Mohrbacher, Ann, Allen S. Yang, Susan Groshen, et al.. (2017). Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clinical Cancer Research. 23(16). 4550–4555. 28 indexed citations
8.
9.
10.
López-Barcons, Lluís, Min H. Kang, Barry J. Maurer, & C. Patrick Reynolds. (2012). Abstract 2493: Enhanced activity of fenretinide/-LYM-X-SORBTM (4-HPR/LXS) oral powder in combination with ketoconazole and vincristine against recurrent neuroblastoma xenografts. Cancer Research. 72(8_Supplement). 2493–2493.
11.
Seidel, Diana, Srinivas S. Somanchi, Dean A. Lee, et al.. (2012). Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. Journal of Molecular Medicine. 91(4). 459–472. 17 indexed citations
12.
Cooper, Jason P., Kyunghwa Hwang, Dong Wang, et al.. (2011). Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. British Journal of Pharmacology. 163(6). 1263–1275. 32 indexed citations
13.
Cheung, Eric, Jacek Pinski, Tanya B. Dorff, et al.. (2009). Oral Fenretinide in Biochemically Recurrent Prostate Cancer: A California Cancer Consortium Phase II Trial. Clinical Genitourinary Cancer. 7(1). 43–50. 23 indexed citations
14.
Reynolds, C. Patrick, Min H. Kang, Nino Keshelava, & Barry J. Maurer. (2007). Assessing Combinations of Cytotoxic Agents Using Leukemia Cell Lines. Current Drug Targets. 8(6). 765–771. 4 indexed citations
15.
Wu, Jun & Barry J. Maurer. (2006). Dihydroceramide desaturases are differentially expressed in Fenretinide-resistant pediatric Acute Lymphoblastic Leukemia (ALL) cell lines. Cancer Research. 66. 297–297. 1 indexed citations
16.
Wang, Hongtao & Barry J. Maurer. (2006). Fenretinide increased ceramides through progressive de novo synthesis and inhibition of sphingomyelin synthesis in a neuroblastoma cell line. Cancer Research. 66. 1093–1093. 1 indexed citations
17.
Moore, Jeff D., et al.. (2006). Liquid chromatography method for quantifying d-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (d-threo-PPMP) in mouse plasma and liver. Journal of Chromatography B. 837(1-2). 44–48. 1 indexed citations
18.
Keshelava, Nino, et al.. (2005). Cyclophosphamide, but not melphalan or carboplatin, synergistically enhanced topotecan activity against Ewing’s family tumor cell lines in hypoxia. Cancer Research. 65. 1111–1112. 1 indexed citations
19.
Reynolds, C. Patrick, Barry J. Maurer, & Richard Kolesnick. (2004). Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Letters. 206(2). 169–180. 271 indexed citations
20.
Reynolds, C. Patrick, Katherine K. Matthay, Judith G. Villablanca, & Barry J. Maurer. (2003). Retinoid therapy of high-risk neuroblastoma. Cancer Letters. 197(1-2). 185–192. 263 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio F. Santidrián Breakdown of academic impact, for papers by Ghita Ghislat Breakdown of academic impact, for papers by Petra Obexer Breakdown of academic impact, for papers by Belamy B. Cheung Breakdown of academic impact, for papers by Martin Augustin Breakdown of academic impact, for papers by Raquel García-Medina Breakdown of academic impact, for papers by Maria Stella Ritorto Breakdown of academic impact, for papers by Daichao Xu Breakdown of academic impact, for papers by Thomas P. Garner
Rankless by CCL
2026